BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Receptor.AI and Moexa Harness AI for SMAD3-Targeted Oncology and Fibrosis

by Roman Kasianov   •   Feb. 10, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Novel Therapeutics   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Receptor.AI and Moexa Pharmaceuticals Limited have announced a partnership to accelerate the development of Moexa’s SMAD3 inhibitors for cancer and fibrosis. The collaboration aims to integrate AI-driven drug discovery workflows with Moexa’s small molecule inhibitors, which have shown promising preclinical results.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

SMAD3 is said to be a central mediator of the TGF-β pathway, driving disease processes like tumor progression and fibrosis through excessive extracellular matrix deposition and immune suppression in the tumor microenvironment. By inhibiting SMAD3, Moexa aims to disrupt these pathological mechanisms. The company, headquartered in West Haven, Connecticut (US), recently secured broad Markush claims from the US Patent & Trademark Office for its SMAD3 inhibitor compounds. Developed with US$32 million in funding, including US$17 million from NIH grants, Moexa’s pipeline has demonstrated dose-dependent efficacy in preclinical studies—enhancing NK cell proliferation, reducing tumor angiogenesis, and mitigating matrix degradation—all without the toxicity typically associated with TGF-β therapies.

See also: From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Receptor.AI brings its modular, AI-based drug discovery workflows to the collaboration, applying computational tools refined across more than 40 discovery projects. The company’s platforms cover small molecules, peptides, and induced proximity agents, with four of its own internal programs targeting nephropathy (RAI-001, IND-enabling stage), oncology (RAI-002), cardiopathy (RAI-003), and inflammation (RAI-004). Its integration with NVIDIA’s BioNeMo, announced just a year ago in February 2024, showcased advanced virtual screening, ADMET assessment, and automated ligand pose prediction, further accelerating hit identification and lead optimization.

Receptor AI's end-to-end drug discovery workflow; Source: Receptor AI

Topics: Novel Therapeutics   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.